Topic
Invasive lobular carcinoma
About: Invasive lobular carcinoma is a research topic. Over the lifetime, 1627 publications have been published within this topic receiving 40236 citations. The topic is also known as: Lobular carcinoma (morphologic abnormality) & Lobular carcinoma NOS (morphologic abnormality).
Papers published on a yearly basis
Papers
More filters
University of Lausanne1, Memorial Sloan Kettering Cancer Center2, University of North Carolina at Chapel Hill3, Rutgers University4, Harvard University5, University of Southern California6, Broad Institute7, Washington University in St. Louis8, Buck Institute for Research on Aging9, University of British Columbia10, Van Andel Institute11, The Chinese University of Hong Kong12, University of Utah13, Stanford University14, University of California, San Francisco15, United States Department of Veterans Affairs16, University of Pittsburgh17, University of Texas MD Anderson Cancer Center18, BC Cancer Agency19
TL;DR: This multidimensional molecular atlas sheds new light on the genetic bases of ILC and provides potential clinical options, suggesting differential modulation of ER activity in I LC and IDC.
1,414 citations
TL;DR: In nonfatty breasts, US and MR imaging were more sensitive than mammography for invasive cancer, but both MR imaging and US involved risk of overestimation of tumor extent.
Abstract: PURPOSE: To prospectively assess accuracy of mammography, clinical examination, ultrasonography (US), and magnetic resonance (MR) imaging in preoperative assessment of local extent of breast cancer. MATERIALS AND METHODS: Institutional review board approval and informed patient consent were obtained. Results of bilateral mammography, US, and contrast-enhanced MR imaging were analyzed from 111 consecutive women with known or suspected invasive breast cancer. Results were correlated with histopathologic findings. RESULTS: Analysis included 177 malignant foci in 121 cancerous breasts, of which 89 (50%) foci were palpable. Median size of 139 invasive foci was 18 mm (range, 2–107 mm). Mammographic sensitivity decreased from 100% in fatty breasts to 45% in extremely dense breasts. Mammographic sensitivity was highest for invasive ductal carcinoma (IDC) in 89 of 110 (81%) cases versus 10 of 29 (34%) cases of invasive lobular carcinoma (ILC) (P < .001) and 21 of 38 (55%) cases of ductal carcinoma in situ (DCIS) (...
1,321 citations
Book•
01 Jan 1997
TL;DR: Preface Preface to The First Edition Acknowledgments Introduction Anatomy and Physiological Morphology Abnormalities of Mammary Growth and Development Inflammatory and Reactive Tumors Specific Infections Papilloma and Related Benign Tumours Myoepithelial Neoplasms Adenosis and Microglandular Adenosis Fibroepithetical Neoplasm Ductal Hyperplasia.
Abstract: Preface Preface to The First Edition Acknowledgments Introduction Anatomy and Physiological Morphology Abnormalities of Mammary Growth and Development Inflammatory and Reactive Tumors Specific Infections Papilloma and Related Benign Tumors Myoepithelial Neoplasms Adenosis and Microglandular Adenosis Fibroepithelial Neoplasms Ductal Hyperplasia: Usual and Atypical Precancerous Breast Disease: Epidemiological, Pathological and Clinical Considerations Intraductal Carcinoma Invasive Duct Carcinoma: Assessment of Prognosis, Morphologic Prognostic Markers, and Tumor Growth Rate Tubular Carcinoma Papillary Carcinoma Medullary Carcinoma Carcinoma with Metaplasia Squamous Carcinoma Mucinous Carcinoma Apocrine Carcinoma Mammary Carcinomas with Endocrine Features Small Cell (Oat Cell) Carcinoma Secretory Carcinoma Mammary Carcinoma with Osteoclast Like Giant Cells Cystic Hypersecretory Carcinoma and Cystic Hypersecretory Hyperplasia Adenoid Cystic Carcinoma Cribriform Carcinoma Lipid-Rich Carcinoma Glycogen-Rich Carcinoma Invasive Micropapillary Carcinoma Paget's Disease of the Nipple Lobular Carcinoma In Situ and Atypical Lobular Hyperplasia Invasive Lobular Carcinoma Unusual Clinical Presentations of Carcinoma Metastases in the Breast from Non Mammary Malignant Neoplasms Benign Proliferative Lesions of the Male Breast Carcinoma of the Male Breast Breast Tumors in Children Benign Mesenchymal Neoplasms Sarcoma Lymphoid and Hematopoietic Tumors Pathologic Effects of Therapy Cutaneous Neoplasms The Pathology of Axillary and Intramammary Lymph Nodes Pathologic Examination of Breast and Lymph Node Specimens Including Sentinel Lymph Nodes Index
962 citations
TL;DR: Despite the fact that the biologic phenotype of ILC is quite favorable, these patients do not have better clinical outcomes than do patients with IDC, and management decisions should be based on individual patient and tumor biologic characteristics.
Abstract: Invasive lobular carcinoma (ILC) comprises approximately 10% of breast cancers and appears to have a distinct biology. Because it is less common than infiltrating ductal carcinoma (IDC), few data have been reported that address the biologic features of ILC in the context of their clinical outcome. In the present study we undertook an extensive comparison of ILC and IDC using a large database to provide a more complete and reliable assessment of their biologic phenotypes and clinical behaviors. The clinical and biological features of 4140 patients with ILC were compared with those of 45,169 patients with IDC (not otherwise specified). The median follow-up period was 87 months. In comparison with IDC, ILC was significantly more likely to occur in older patients, to be larger in size, to be estrogen and progesterone receptor positive, to have lower S-phase fraction, to be diploid, and to be HER-2, p53, and epidermal growth factor receptor negative. It was more common for ILC than for IDC to metastasize to the gastrointestinal tract and ovary. The incidence of contralateral breast cancer was higher for ILC patients than for IDC patients (20.9% versus 11.2%; P < 0.0001). Breast preservation was modestly less frequent in ILC patients than in IDC patients. The 5-year disease-free survival was 85.7% for ILC and 83.5% for IDC (P = 0.13). The 5-year overall survival was 85.6% for ILC and 84.1% for IDC (P = 0.64). Despite the fact that the biologic phenotype of ILC is quite favorable, these patients do not have better clinical outcomes than do patients with IDC. At present, management decisions should be based on individual patient and tumor biologic characteristics, and not on lobular histology.
748 citations
Nottingham City Hospital1, University of California, San Francisco2, University of Pittsburgh3, University of Münster4, Peter MacCallum Cancer Centre5, Royal Brisbane and Women's Hospital6, Brigham and Women's Hospital7, Beth Israel Deaconess Medical Center8, University of Porto9, Singapore General Hospital10, Indiana University – Purdue University Indianapolis11
TL;DR: In this paper, the authors present an analysis of the validity of histological grade as a prognostic factor and a consensus view on the significance of histology grade and its role in breast cancer classification and staging systems.
Abstract: Breast cancer is a heterogeneous disease with varied morphological appearances, molecular features, behavior, and response to therapy. Current routine clinical management of breast cancer relies on the availability of robust clinical and pathological prognostic and predictive factors to support clinical and patient decision making in which potentially suitable treatment options are increasingly available. One of the best-established prognostic factors in breast cancer is histological grade, which represents the morphological assessment of tumor biological characteristics and has been shown to be able to generate important information related to the clinical behavior of breast cancers. Genome-wide microarray-based expression profiling studies have unraveled several characteristics of breast cancer biology and have provided further evidence that the biological features captured by histological grade are important in determining tumor behavior. Also, expression profiling studies have generated clinically useful data that have significantly improved our understanding of the biology of breast cancer, and these studies are undergoing evaluation as improved prognostic and predictive tools in clinical practice. Clinical acceptance of these molecular assays will require them to be more than expensive surrogates of established traditional factors such as histological grade. It is essential that they provide additional prognostic or predictive information above and beyond that offered by current parameters. Here, we present an analysis of the validity of histological grade as a prognostic factor and a consensus view on the significance of histological grade and its role in breast cancer classification and staging systems in this era of emerging clinical use of molecular classifiers.
615 citations